| Autor: |
Thieblemont, C., Karimi, Y., Jurczak, W., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Lewis, D. J., Gasiorowski, R., Kim, T. M., van der Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Cottereau, A., Al Tabaa, Y., Stirner, M. Cota, Liu, Y. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p142-144, 3p |
| Abstrakt: |
B Introduction: b Outcomes are poor for patients with relapsed/refractory ( I R i / I R i ) large B-cell lymphoma (LBCL). SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text